ABOUT BERKELEY LIGHTS

Berkeley Lights is a leading Digital Cell Biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products for our customers. The Berkeley Lights Platform captures deep phenotypic, functional and genotypic information for thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells.

APPLICATION NOTES

  • We demonstrate a workflow that can be used to access broad plasma cell diversity and rapidly down-select lead candidates with functional profiling.

  • Understanding the genetic mechanisms of T cell polyfunctionality could be critical for developing effective therapeutics. The Opto™ Cell Therapy Development workflow makes it possible to identify these mechanisms by characterizing function at the single-cell level and linking phenotypic data to individual gene expression profiles.

  • To harness their full therapeutic potential, we must understand the relationship between target cell killing and other critical functions of individual T cells. Our platform can be used to interrogate antigen-specific serial killing activity of single CAR T cells and correlate this to cytokine secretion and proliferation while preserving individual T cells for downstream analyses or expansion.

  • Current experimental methods to characterize NK cells rely on bulk measurements of heterogenous samples that often contain contaminating cell types. In this application note, we demonstrate how NK cell function can be assessed at the single-cell level to characterize both cytotoxicity and ADCC mediation in the presence of target cells.

  • Current techniques used to assess T cell function only allow us to draw correlative conclusions. This application note demonstrates how the Berkeley Lights platform can directly link phenotype to genotype to identify differences in CAR T cell killing kinetics as well as to recover TCR sequences that are associated with desired killing behavior.

  • This application note demonstrates how the Berkeley Lights platform can be used to identify single T cells that maintain proliferative ability while secreting specific cytokine combinations and exhibiting desired tumor killing activity.   

VIDEOS

  • Polyfunctional T cells are considered the most potent anti-tumor effector T cells. Originally presented in early 2021, this webinar features Dr. Jason McEwen, the Director Biology at Berkeley Lights, as he reviews how to use a multi-omic workflow to find and fully profile polyfunctional T cells for more effective therapies.

  • CAR T therapy in children with leukemia was the first FDA-approved gene modified cell therapy.  Dr. David M Barrett, one of the developers of this therapy, shares new insight into Naïve T cells and how chemotherapy impacts their function.

  • Immunogenicity validation is a critical bottleneck in the tumor antigen discovery process in part because the vast majority of candidate neoantigens identified in a tumor are not recognized by T cells. This product tour shows how the Opto™ Antigen Presenting Bead Kit and Opto™ Cell Therapy Development workflow address this bottleneck.

CONTACT INFORMATION

Berkeley Lights

5858 Horton St, Suite 320

Emeryville, CA 94608

UNITED STATES

Phone: 510-585-2855

BROCHURES

  • Our T cell workflow allows you to investigate complex cell-cell interactions. Our portfolio of capabilities includes assays to study polyfunctionality, cytotoxicity and the ability to directly link phenotype to gene expression.

  • The Opto™ Cell Therapy Development worfklow accelerates the creation of better therapeutics by enabling multiple functional assays to be performed simultaneously on 1000s of individual T cells in a matter of days. Deeply characterize, profile, and map your T cell populations at the single-cell level to directly link behavior to gene expression.

  • Find out how the Opto™ Cell Line Development workflow sets a new standard for quality, capacity, and speed in cell line development to let BioPharma get more molecules to the clinic faster.

  • Identifying T cell functional signatures is a long, laborious, and complex process that requires you to draw conclusions from surrogate measurements collected on multiple platforms. The Lightning system changes this by allowing you to directly visualize the phenotype and function of 1000s of individual cells in just days and recover cells of interest alive. 

  • Antigen-specific T cells can be selectively expanded using the Opto™ Antigen Presenting Bead kit upstream of the Opto™ Cell Therapy Development workflow, enabling you to directly link peptide binding and recognition to antigen specific effector function.

  • Cytokine assays in the Opto™ Cell Therapy Development workflow allow simultaneous functional interrogation of thousands of individual T cells as they interact with antigen-presenting cells, granting insight into the heterogenous mechanisms that regulate cytokine secretion. The automated assays also allow live recovery of individual clones for downstream analysis. Cytokine assays and cell surface markers can be customized.

  • The Opto™ Cell Therapy Development workflow Cytotoxicity Assay  enables kinetic analysis of killing activity from single T cells, followed by live cell recovery for genomic analysis. This assay avoids common problems associated with traditional killing assays, which measure average target cell lysis at fixed time points, obscuring kinetic details and ignoring the heterogeneity present in T cell subsets.

  • Identifying T cell functional signatures is a long, laborious, and complex process that requires you to draw conclusions from surrogate measurements collected on multiple platforms. The Lightning system changes this by allowing you to directly visualize the phenotype and function of 1000s of individual cells in just days and recover cells of interest alive.

  • Used downstream of functional T cell assays in the Opto™ Cell Therapy Development workflows, the TCRseq kit enables recovery of functionally validated T cell receptors (TCRs) from fewer than 10,000 input cells. Instead of re-expressing hundreds of TCRs in the hopes of identifying the rare sequence that imparts ideal specificity, the kit allows users to only sequence the T cells that matter.